Kodiak Sciences downgraded by CapitalOne with a new price target
$KOD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CapitalOne downgraded Kodiak Sciences from Overweight to Equal Weight and set a new price target of $7.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/14/2025 | $15.00 | Underweight → Neutral | Analyst |
| 12/9/2024 | $20.00 | Hold → Buy | Jefferies |
| 9/5/2024 | $3.00 | Neutral | H.C. Wainwright |
| 12/11/2023 | $2.00 | Sell | Goldman |
| 11/17/2023 | $7.00 → $12.00 | Equal Weight → Overweight | CapitalOne |
| 7/27/2023 | $15.00 → $4.00 | Buy → Neutral | UBS |
| 7/25/2023 | Buy → Neutral | Chardan Capital Markets | |
| 7/25/2023 | Neutral → Underweight | JP Morgan |
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
Analyst upgraded Kodiak Sciences from Underweight to Neutral and set a new price target of $15.00
Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00
H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00
PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets –tarcocimab, KSI-501 and KSI-101– underscoring their transformative potential in retinal disease treatment," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to inflammation (ME
PALO ALTO, Calif. , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025, from 4:00 pm ET to 5:30 pm ET. The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of Kodiak's senior leadership team complemented by distinguished industry experts. A live webcast of this event will be available to investors and other interested parties. Registration for
PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion leaders will present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, Brazil on Friday, June 27, 2025. "We are excited to participate in this year's IOIS meeting and connect with leading experts in ocular inflammation to help advance care for patients with macular edema caused by inflammation," said Pablo Velazquez-Martin, MD, Chief
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive
PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje